Research Analysts Issue Forecasts for CervoMed Q1 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Analysts at Roth Capital decreased their Q1 2025 earnings per share (EPS) estimates for CervoMed in a research report issued on Tuesday, March 18th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will post earnings per share of ($0.80) for the quarter, down from their prior estimate of ($0.52). Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Roth Capital also issued estimates for CervoMed’s Q2 2025 earnings at ($0.73) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($2.47) EPS.

CervoMed (NASDAQ:CRVO) last posted its quarterly earnings data on Monday, March 17th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). CervoMed had a negative return on equity of 44.11% and a negative net margin of 118.68%. The company had revenue of $2.16 million for the quarter, compared to the consensus estimate of $1.51 million.

CRVO has been the topic of a number of other research reports. Jones Trading upgraded CervoMed from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research note on Thursday, March 13th. Brookline Capital Management raised CervoMed from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 11th. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of CervoMed in a report on Monday, March 17th. Roth Mkm raised their target price on CervoMed from $15.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Chardan Capital raised CervoMed from a “neutral” rating to a “buy” rating and set a $14.00 price objective on the stock in a report on Thursday, March 13th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $27.50.

CervoMed Price Performance

CervoMed stock opened at $14.29 on Thursday. The stock’s fifty day moving average price is $3.30 and its two-hundred day moving average price is $7.87. CervoMed has a one year low of $1.80 and a one year high of $25.92. The firm has a market cap of $88.17 million, a PE ratio of -7.04 and a beta of 1.84.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CRVO. Virtu Financial LLC bought a new position in CervoMed during the 4th quarter worth $26,000. DRW Securities LLC bought a new position in CervoMed during the 4th quarter worth $30,000. Mariner LLC bought a new position in CervoMed during the 4th quarter worth $30,000. BNP Paribas Financial Markets bought a new position in CervoMed during the 4th quarter worth $32,000. Finally, JPMorgan Chase & Co. raised its position in CervoMed by 251.8% during the 4th quarter. JPMorgan Chase & Co. now owns 14,464 shares of the company’s stock worth $34,000 after purchasing an additional 10,352 shares during the last quarter. 25.15% of the stock is owned by institutional investors.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.